

April 1, 2026

---

**Vetanic Enters into Capital and Business Alliance with  
Sysmex Corporation and Kohjin Bio Co., Ltd.**  
— **Strengthening R&D and Business Infrastructure in Regenerative Medicine  
and Cell Therapy** —

Vetanic Inc. (Headquarters: Minato-ku, Tokyo; CEO: Akinori Mochizuki; hereinafter “Vetanic”) hereby announces that it has entered into a capital and business alliance agreement with Sysmex Corporation (TSE Prime: 6869; Headquarters: Kobe, Hyogo; hereinafter “Sysmex”) and Kohjin Bio Co., Ltd. (TSE Growth: 177A; Headquarters: Sakado, Saitama; hereinafter “Kohjin Bio”).

**Background and Purpose of the Alliance**

Vetanic has been advancing research and development aimed at the social implementation of cell therapy and regenerative medicine in the field of veterinary medicine using iPS cell technology.

Sysmex is a global leader in the clinical diagnostics field based on advanced analytical technologies. In addition to human healthcare, Sysmex is also engaged in the veterinary field and has strengths in regenerative medicine, including cell evaluation and quality control, as well as automation of cell manufacturing using robotics technologies.

Kohjin Bio, on the other hand, possesses strong capabilities in developing custom culture media tailored to diverse customer needs, comprehensive manufacturing support from research to production, and a stable supply network for a wide range of regenerative medicine-related materials. The company is expanding its business in Japan and across Asia. Vetanic had previously entered into a business alliance with Kohjin Bio in November 2024 to leverage these strengths for its product development.

Under this agreement, Vetanic has executed a third-party allotment of new shares with Sysmex and Kohjin Bio as allottees, thereby establishing a capital alliance. Through this partnership, the three companies will integrate their respective strengths and accelerate the following initiatives:

- Advancement of R&D and quality evaluation technologies for cell therapy (iMSC) products
- Establishment and scale-up of manufacturing processes and supply systems
- Promotion of translational medicine between veterinary and human healthcare based on the One Health concept

## **Strategic Benefits of the Alliance**

Through this alliance, Vetanic will strengthen relationships via capital participation and gain operational synergies by leveraging the technological advantages of both partners:

- Development of animal cell evaluation systems utilizing Sysmex's diagnostic and analytical technologies
- Promotion of high-quality regenerative medicine product development using Kohjin Bio's culture media and related materials
- Creation of new business opportunities through joint initiatives among the three companies, including conditioned media and alternatives to animal testing

## **Future Outlook**

Through this capital and business alliance, Vetanic will strengthen its value chain from R&D to manufacturing, quality control, and commercialization, thereby accelerating the provision of innovative therapeutic options in the form of high-quality, iPS cell-derived regenerative medicine for animals that can become a global standard.

In addition to developing iMSC products for dogs, cats, and horses, Vetanic will explore the use of conditioned media derived from iMSCs and the development of alternative methods to animal testing using various iPS cell-derived cell types. Looking ahead, Vetanic also aims to expand into human healthcare, enhancing its global competitiveness and corporate value.

### **What are iPS Cells?**

Induced pluripotent stem (iPS) cells are pluripotent stem cells artificially generated from adult somatic cells. Professor Shinya Yamanaka of Kyoto University and his team successfully created these cells by introducing four reprogramming genes into differentiated somatic cells such as skin cells, enabling them to develop into any tissue type like fertilized eggs. This groundbreaking achievement was recognized with the Nobel Prize in Physiology or Medicine in 2012.

Today, numerous regenerative medicine technologies based on iPS cells are being developed worldwide, and in Japan, two human iPS cell-derived regenerative medicine products have already been approved. However, establishing stable and efficient iPS cells in animal species such as dogs and cats has historically been challenging. Vetanic has overcome this barrier and successfully established animal iPS cells suitable for clinical applications.

### **What are Mesenchymal Stromal/Stem Cells (MSCs)?**

MSCs are a type of somatic stem cell present in the body, known for their ability to suppress excessive inflammation by secreting various anti-inflammatory factors such as cytokines. As a result, they are widely being developed in regenerative medicine (stem cell therapy) for both human and veterinary applications.

MSC-based regenerative medicine products have already been approved and are being used clinically. However, conventional MSCs are derived from donor tissues such as adipose tissue, bone marrow, or peripheral blood, making donor dependency unavoidable. In contrast, iPS cell-derived MSCs do not require donors and are reported to have higher uniformity, making them a promising next-generation cell therapy.

### **About Vetanic Co., Ltd.**

Vetanic is a university-originated startup officially recognized by Nihon University, established in January 2021 based on joint research outcome between Nihon University and Keio University. Leveraging its proprietary technology for establishing clinically applicable animal iPS cells, Vetanic develops high-quality regenerative medicine products—including mesenchymal stem cells—from iPS cells of dogs, cats, and horses. By providing donor-free and sustainable therapeutic options, Vetanic aims to realize animal regenerative medicine as a global standard.

### **About Sysmex Corporation**

Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives.

\* "Healthcare journey" is a trademark of Sysmex Corporation, registered in Japan.

For more information about Sysmex, please visit [www.sysmex.co.jp/en/](http://www.sysmex.co.jp/en/)

### **About Kohjin Bio Co., Ltd.**

Founded in April 1981, Kohjin Bio Co., Ltd. is engaged in the manufacturing and sale of culture media for cell culture, in vitro diagnostic reagents, and microbiological media, as well as contract cell processing services.

In recent years, with the rapid global expansion of the regenerative medicine market, the company has been focusing on R&D of culture media used in cell cultivation and is actively expanding its business in the regenerative medicine field both domestically and internationally.

For more information about Kohjin Bio Co., Ltd., please visit [www.kohjin-bio.jp/en/](http://www.kohjin-bio.jp/en/)

### **Contact Information**

Vetanic Inc.

Email: [contact@vetanic.com](mailto:contact@vetanic.com)